An Open-label, Single-centre, Randomised, Two-period Crossover Study to Assess the Efficacy and Safety of 24-hour Closed-loop Glucose Control in Comparison With Conventional Treatment in Adults With Type 2 Diabetes on Non-insulin Glucose-lowering Agents
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Percent of plasma glucose values within target range 3.9-8.0 mmol/l
研究概览
简要总结
The main objective of this study is to evaluate the efficacy and safety of 24 hours of closed-loop glucose control compared with standard diabetes treatment, in patients with type 2 diabetes treated by non-insulin glucose-lowering medications. This group is being studied as it is representative of patients with glucose dysregulation.
详细描述
Algorithm driven closed-loop enables automated subcutaneous delivery of insulin in response to real-time continuous glucose sensor readings. Our studies to date have assessed the safety and efficacy of closed-loop insulin delivery in patients with type 1 diabetes in a controlled setting. For patients with type 2 diabetes treated by diet or non-insulin glucose-lowering medications alone, an episode of acute illness may result in elevated glucose levels necessitating initiation of insulin replacement therapy to optimise glycaemic control. Insulin may also be required in patients with no prior history of diabetes, presenting with 'stress hyperglycaemia'. Closed-loop systems may be of benefit in such insulin-naive patients in whom the optimal dosing regimen is difficult to establish, and may provide a safer method of insulin delivery with the added benefit of continuous monitoring of glucose levels on general hospital wards, thus minimising the likelihood of hyper- and hypoglycaemic events and their known associated worse outcomes.
The study has an open-label, randomised, two-period crossover design. Participants will be randomised to undergo two 24-hour studies in a clinical research facility, during which glucose levels will be controlled by either the computer-based closed-loop algorithm (intervention) or by patients' usual non-insulin glucose-lowering diabetes treatment regimen (control). A continuous glucose sensor will be inserted on arrival for each visit. Participants will consume regular meals (matched on both visits) and carry out daily activities mimicking those occurring in an inpatient setting. Stable glucose isotopes will be administered on the two study occasions to collect data for modeling of glucose turnover around meals and during the overnight period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 years or older
- •Type 2 diabetes for at least 1 year as defined by WHO
- •Treatment with glucose-lowering medication(s) (including Exenatide) for at least 6 mths
- •HbA1c between 7.0% and 10.0% inclusive (measured within past 3 mths)
排除标准
- •Autoimmune type 1 diabetes
- •Type 2 diabetes treated with insulin
- •Type 2 diabetes treated with diet control alone
- •Known or suspected allergy against insulin
- •Proliferative retinopathy
- •Current or planned pregnancy or breast feeding
- •Any physical or psychological disease or medication(s) likely to interfere with the conduct of the study and interpretation of the study results, as judged by the study clinician
研究组 & 干预措施
closed-loop insulin delivery
Subcutaneous insulin delivery adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
干预措施: closed-loop insulin delivery (Procedure)
Usual diabetes treatment regimen
Usual non-insulin glucose-lowering medications
干预措施: Usual diabetes treatment regimen (Drug)
结局指标
主要结局
Percent of plasma glucose values within target range 3.9-8.0 mmol/l
时间窗: 24 hrs
次要结局
- Percent of sensor glucose values within target range 3.9-8.0 mmol/l(24 hrs)
- Percent of plasma and sensor glucose values below 3.9 mmol/l(24 hrs)
- Percent of plasma and sensor glucose values above 8.0 mmol/l(24 hrs)
- Mean plasma and sensor glucose(24 hrs)
- Mean plasma insulin concentration(24 hrs)
- Total basal insulin insulin delivery(24 hrs)
- Low blood glucose index (LBGI) score(24 hrs)
- High blood glucose index (HBGI) score(24 hrs)
- Hyperglycaemic index score(24 hrs)
- Percent of plasma and sensor glucose values below 3.0 mmol/l(24 hrs)
- Standard deviation of plasma glucose(24 hrs)
- Frequency of hypoglycaemia(24 hrs)
- Frequency of hyperglycaemia(24 hrs)
研究者
Kavita Kumareswaran
Clinical Research Fellow
University of Cambridge